osimertinib,tepotinib
astrazeneca,merck
['osimertinib', 'insight 2', 'nsclc', 'sclc', 'tepotinib']
insight 2 trial suggests better response to combination of osimertinib +tepotinib (54.5%) than tepotinib alone in egfr+ve nsclc after 1st line osimertinib alone with met amplification #esmo22 
Consultant Oncology Pharmacist, Airedale NHSFT. Honorary Lecturer @BradfordUni. @BOPA Fellow. Very amateur gardener and brewer.